Research programme: DNA repair inhibitors - Ignyta/Cancer Research Technology

Drug Profile

Research programme: DNA repair inhibitors - Ignyta/Cancer Research Technology

Alternative Names: RXDX-108; TEV-44229

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology; Teva Pharmaceutical Industries
  • Developer Cancer Research Technology; Ignyta
  • Class Small molecules
  • Mechanism of Action DNA repair inhibitors; Protein kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Mar 2016 Ignyta has patents pending for RXDX 108 in USA (Ignyta 10-K, March 2016)
  • 26 Feb 2016 Discontinued - Preclinical for Cancer in United Kingdom, USA (unspecified route)
  • 17 Mar 2015 Ignyta acquires RXDX 108 and other next generation atypical protein kinase C iota inhibitors from Teva Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top